Clinical Trials - January 8, 2018
Medivir has completed pre-clinical safety studies with MIV-818
Medivir announces the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018. MIV-818 is Medivir’s liver-targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer. It is the first development project to emerge from Medivir’s in-house drug discovery […]
Pharma Business - December 11, 2017
Janssen decides to terminate its Simeprevir license
Medivir announces that Janssen Pharmaceuticals has decided to terminate the license that it holds for simeprevir due to Janssen’s assessment of market demand. The termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time. Medivir […]
Drug Development Pharma - November 8, 2017
New cancer project for Medivir
Medivir announces a new discovery project for a cancer indication. The Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies, and is based on the company’s expertise in nucleoside and nucleotide science. It represents the second cancer project to emerge from its in-house […]
Clinical Trials - October 16, 2017
Medivir announces Phase II data
Phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions. Remetinostat also caused a clinically significant reduction in the severity of pruritus (itching) in those patients with clinically significant pruritus […]
Clinical Trials - September 5, 2017
Medivir initiates new clinical study
Medivir announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab), which is marketed by MSD. The objectives of the study are to evaluate the safety, tolerability and preliminary efficacy of this combination in patients with treatment-resistant solid tumours. The multicentre, […]
New Market - August 18, 2017
Medivir in license agreement
Medivir and Ascletis announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China. Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered […]
